Quest Diagnostics (NYSE: DGX) CFO reports 102-share dividend reinvestment acquisition
Rhea-AI Filing Summary
Quest Diagnostics Executive Vice President & CFO Sam Samad reported an acquisition of 102 shares of Quest Diagnostics common stock on July 22, 2026, at $206.807 per share in a grant/award transaction, bringing his directly held position to 33,478 shares.
Footnotes state the security represents an award of restricted share units and that the shares were acquired through a dividend reinvestment plan administered by his broker, which is eligible for deferred reporting on Form 5 under Rule 16a-6 but was voluntarily reported early.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 102 shares
Net Buy
1 txn
Insider
SAMAD SAM
Role
Executive Vice President & CFO
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock F1, F2 | 102 | $206.807 | $21K |
Holdings After Transaction:
Common Stock — 33,478 shares (Direct)
Footnotes (2)
- F1. Represents an award of restricted share units.
- F2. Reflects shares that were acquired pursuant to a dividend reinvestment plan administered by the reporting person's broker and eligible for deferred reporting on Form 5 under Rule 16a-6. The reporting person has chosen to report such transaction early on this Form 4.
Key Figures
Shares acquired: 102 shares
Price per share: $206.807 per share
Shares held after transaction: 33,478 shares
3 metrics
Shares acquired
102 shares
Grant/award acquisition of common stock on July 22, 2026
Price per share
$206.807 per share
Reported transaction price for the July 22, 2026 acquisition
Shares held after transaction
33,478 shares
Directly owned Quest Diagnostics common stock following the reported Form 4 transaction
Key Terms
restricted share units, dividend reinvestment plan, Rule 16a-6, Form 5
4 terms
dividend reinvestment plan financial
"Shares were acquired pursuant to a dividend reinvestment plan administered by the broker."
A dividend reinvestment plan lets shareholders automatically use cash dividends to buy more shares of the same company instead of receiving the money. It matters to investors because it turns regular payouts into a steady way to grow ownership and take advantage of compound returns—like having your savings automatically buy additional slices of a pie over time—while often reducing transaction costs and smoothing purchase timing.
Rule 16a-6 regulatory
"The transaction is eligible for deferred reporting on Form 5 under Rule 16a-6."
Form 5 regulatory
"Eligible for deferred reporting on Form 5 under Rule 16a-6 but reported early."
A Form 5 is an annual report filed with the U.S. securities regulator by company insiders—such as officers, directors and large shareholders—to disclose any equity transactions or holdings that were missed or deferred during the year. Think of it as an end-of-year ledger adjustment that shows final insider ownership and late-reported trades; investors use it to verify insider confidence, detect possible conflicts of interest, and spot unusual patterns in insiders’ buying or selling.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider transaction did Quest Diagnostics (DGX) CFO Sam Samad report on this Form 4?
Sam Samad reported acquiring 102 shares of Quest Diagnostics common stock on July 22, 2026 in a grant/award transaction at $206.807 per share, increasing his directly held stake to 33,478 shares according to the Form 4 data.
What type of equity award did the Quest Diagnostics (DGX) CFO receive in this Form 4 filing?
Footnotes state the transaction represents an award of restricted share units. Although the security is labeled common stock, the note clarifies that the reported holding reflects restricted share units granted to Sam Samad as part of this acquisition.
Was Sam Samad’s Quest Diagnostics (DGX) transaction connected to a dividend reinvestment plan?
Yes. Footnotes explain the 102 shares reflect stock acquired under a dividend reinvestment plan administered by his broker. The transaction was eligible for deferred reporting on Form 5 under Rule 16a-6 but was instead reported early on this Form 4.